| gap-pubmed-20260406- | Does SPP1-mediated synaptic engulfment represent beneficial clearance or patholo | partially_addressed | 0.83 | 0.00 | 2026-04-06 | 0 | | synaptic-biology |
| gap-pubmed-20260406- | How do perivascular cells specifically recognize and respond to amyloid-β to upr | partially_addressed | 0.85 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What molecular mechanisms mediate SPP1-induced microglial phagocytic activation | resolved | 0.89 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |
| gap-pubmed-20260406- | Why do clinical manifestations overlap despite distinct underlying etiologies in | partially_addressed | 0.69 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |
| gap-pubmed-20260406- | What are the specific pathophysiological mechanisms underlying uncommon immune-m | partially_addressed | 0.76 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |
| gap-debate-20260406- | What is the optimal therapeutic window timing for autophagy enhancement versus s | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | molecular-biology |
| gap-debate-20260406- | Can metabolic interventions truly reverse established cellular senescence or onl | partially_addressed | 0.75 | 0.00 | 2026-04-06 | 0 | | cell-biology |
| gap-debate-20260406- | Do APOE4-driven senescent astrocytes cause neurodegeneration or represent a prot | partially_addressed | 0.85 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-debate-20260406- | How can senescent microglia be molecularly distinguished from beneficial activat | partially_addressed | 0.90 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-debate-20260406- | How can ESCRT or SNARE targeting achieve tau-specific effects without disrupting | partially_addressed | 0.75 | 0.00 | 2026-04-06 | 0 | | molecular-biology |
| gap-debate-20260406- | Can chaperone enhancement approaches overcome tau seed saturation effects in adv | partially_addressed | 0.85 | 0.00 | 2026-04-06 | 0 | | protein-folding |
| gap-debate-20260406- | Which tau propagation mechanism predominates in different brain regions and dise | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-debate-20260406- | What is the therapeutic window between tau propagation inhibition and essential | partially_addressed | 0.90 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-debate-20260406- | Do perinatal immune challenges create persistent epigenetic modifications that p | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | developmental-neurobiology |
| gap-debate-20260406- | Can IGFBPL1 therapeutics effectively cross the blood-brain barrier to reach CNS | partially_addressed | 0.90 | 0.00 | 2026-04-06 | 0 | | drug-delivery |
| gap-debate-20260406- | What is the optimal therapeutic window for microglial reprogramming before irrev | partially_addressed | 0.85 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-debate-20260406- | Why do systemic anti-inflammatory drugs fail in AD despite cardiovascular effica | partially_addressed | 0.75 | 0.00 | 2026-04-06 | 0 | | clinical-neurology |
| gap-debate-20260406- | How can CNS-selective HDAC/DNMT inhibitors be developed to avoid systemic toxici | partially_addressed | 0.78 | 0.00 | 2026-04-06 | 0 | | pharmacology |
| gap-debate-20260406- | Do different priming stimuli require distinct therapeutic approaches or share co | partially_addressed | 0.75 | 0.00 | 2026-04-06 | 0 | | immunology |
| gap-debate-20260406- | What biomarkers can reliably detect microglial priming states in living patients | partially_addressed | 0.88 | 0.00 | 2026-04-06 | 0 | | biomarkers |
| gap-debate-20260406- | What is the optimal therapeutic window during preclinical AD for epigenetic repr | partially_addressed | 0.82 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-debate-20260406- | Can circadian interventions reverse microglial priming independent of sleep disr | partially_addressed | 0.75 | 0.00 | 2026-04-06 | 0 | | chronobiology |
| gap-debate-20260406- | Do microglia actually switch between glycolytic and oxidative phosphorylation as | partially_addressed | 0.82 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |
| gap-debate-20260406- | Which specific metabolic pathways in APOE4+ microglia are most therapeutically t | partially_addressed | 0.71 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-debate-20260406- | What specific astrocyte-derived factors can 'erase' pathological microglial memo | partially_addressed | 0.78 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |
| gap-pubmed-20260406- | What are the specific molecular mechanisms by which AQP4 dysfunction contributes | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How can AQP4 be effectively targeted therapeutically to improve neurological out | partially_addressed | 0.82 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How do regional, age, and sex-dependent differences in microglial populations af | partially_addressed | 0.86 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |
| gap-pubmed-20260406- | What molecular mechanisms drive microglial senescence and the transition to dyst | partially_addressed | 0.85 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What causes IBA1 low/negative microglia in liver disease and how does this affec | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |
| gap-pubmed-20260406- | What determines P2RY12 receptor expression/activity specifically in VSMCs during | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How does P2RY12-mediated VSMC dysfunction contribute to cerebrovascular neurodeg | partially_addressed | 0.82 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How do pathological stress granules transition from reversible to persistent in | partially_addressed | 0.85 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What determines the specificity of RNA-protein interactions that drive distinct | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How do disease-associated mutations in G3BP1 or its binding partners alter stres | partially_addressed | 0.86 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How do pathological stress granules in neurodegeneration escape TRIM21/autophagy | partially_addressed | 0.85 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What determines the spatial organization of autophagy receptors at stress granul | partially_addressed | 0.79 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How does TRIM21-mediated K63 ubiquitination of G3BP1 mechanistically inhibit liq | partially_addressed | 0.82 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-20260404-120802 | Investigate mechanisms of epigenetic reprogramming in aging neurons | partially_addressed | 0.90 | 0.00 | 2026-04-04 | 0 | | neurodegeneration |
| gap-20260404-microgl | Neuroinflammation and microglial priming in early Alzheimer's Disease | partially_addressed | 0.95 | 0.00 | 2026-04-04 | 0 | | neurodegeneration |
| gap-20260404-060512 | epigenetic reprogramming aging neurons | partially_addressed | 0.90 | 0.00 | 2026-04-04 | 0 | | neurodegeneration |
| gap-20260404-052358 | Investigate prion-like spreading of tau pathology through connected brain region | partially_addressed | 0.90 | 0.00 | 2026-04-04 | 0 | | neurodegeneration |
| gap-neuroinflammatio | Neuroinflammation and microglial priming in early AD | partially_addressed | 0.90 | 0.00 | 2026-04-04 | 0 | | neurodegeneration |
| gap-apoe4-lipid-meta | APOE4-driven lipid metabolism dysregulation in astrocytes and its role in AD | partially_addressed | 0.90 | 0.82 | 2026-04-04 | 0 | | neuroscience |
| gap-lysosomal-cathep | Lysosomal dysfunction and cathepsin leakage in Alzheimer disease progression | partially_addressed | 0.82 | 0.79 | 2026-04-04 | 0 | | neuroscience |
| gap-tau-prion-spread | Trans-synaptic tau spreading and propagation mechanisms in AD | partially_addressed | 0.88 | 0.83 | 2026-04-04 | 0 | | neuroscience |
| gap-neuro-microglia- | Neuroinflammation and microglial priming in early Alzheimer's Disease | partially_addressed | 0.90 | 0.00 | 2026-04-04 | 0 | | neurodegeneration |
| gap-debate-20260403- | Which metabolic biomarkers can distinguish therapeutic response from disease pro | partially_addressed | 0.75 | 0.00 | 2026-04-04 | 0 | | translational-neuroscience |
| gap-debate-20260403- | What determines the optimal timing and dosing of ketogenic interventions for neu | partially_addressed | 0.85 | 0.00 | 2026-04-04 | 0 | | metabolic-neuroscience |
| gap-debate-20260403- | How do astrocyte-neuron metabolic interactions change during disease progression | partially_addressed | 0.80 | 0.00 | 2026-04-04 | 0 | | neurodegeneration |